What is Kyverna Therapeutics, Inc.'s secured lines of credit?

Kyverna Therapeutics, Inc. (KYTX) reported secured lines of credit of $24.81M in Q1 2026.

Kyverna Therapeutics, Inc. KYTX Secured lines of credit

Secured lines of credit at other companies

Dominion EnergyD

$0—

Jefferies Financial GroupJEF

$424.02M+1,807%

Jefferies Financial GroupJEF

$2.29B+0.3%

APO

Apogee EnterprisesAPOG

$33M—

MillerKnollMLKN

$243.8M-8.0%

American Electric PowerAEP

$900M—

Other financials

Income statement

See full

Operating income-$41.4M+12.7%

Net income-$39.7M+11.0%

EPS (diluted)-$0.66+35.9%

Balance sheet

See full

Cash & equivalents$32.2M-43.4%

Total debt$9.2M+32.1%

Total equity$195.6M-12.7%

Total assets$257.0M-1.4%

Cash flow

See full

Operating cash flow-$41.6M+7.4%

CapEx$2.0K-98.0%

Free cash flow-$33.5M+10.8%

Valuation

See full

Market cap$498.52M+276%

Enterprise value$475.49M+475%

Returns & leverage

See full

Return on equity-74.5%+74.4pp

Debt / equity0×0.0×

Current ratio8.1×+0.7×

Where this comes from

Reported directly by Kyverna Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LongTermLineOfCredit.

The official record: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kyverna Therapeutics, Inc.'s secured lines of credit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Kyverna Therapeutics, Inc.'s secured lines of credit?: Kyverna Therapeutics, Inc. (KYTX) reported secured lines of credit of $24.81M in Q1 2026.